Hypertrophic cardiomyopathy in childhood.
Hypertrophic cardiomyopathy has important differences in children compared with adults, particularly with regard to the range of causes and the outcomes in infants. Survival is highly dependent on etiology, particularly in the youngest patients, and pursuit of the specific cause is therefore necessary. The clinical utility of defining the genotype in children with familial hypertrophic cardiomyopathy exceeds that at other ages and has a highly favorable cost/benefit ratio. Although most of the available information concerning treatment and prevention of sudden death is derived in adults, management of children requires consideration of the differences in age-specific risk/benefit ratios.
Colan
Steven D
SD
Department of Cardiology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA. colan@alum.mit.edu
D055011:Ablation Techniques; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000150:complications; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D002648:Child; D003645:Death, Sudden / Q000209:etiology / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D000431:Ethanol; D015444:Exercise; D020022:Genetic Predisposition to Disease; D006346:Heart Septum / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging; D054084:Myocardial Bridging; D009206:Myocardium / Q000473:pathology; D010138:Pacemaker, Artificial; D012720:Severity of Illness Index; D013575:Syncope / Q000150:complications; D014694:Ventricular Outflow Obstruction
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D000431:Ethanol